Given that they will no longer be funding a Phase III clinical for mmd and will likely get some funding for the phase II clinical for severe insulin resistance, I'm not sure where their expenses are. Allan is toast, as is his comp and expense package. Their complete overhead can't be much more than a few million bucks a year. And, between Italy, Canada, the US, Greece and whatever other revenues turn up for ALS, they have to be profitable. Add in a few million in investment income and the company could make $5 - 10 million next year.
All this being said, they seem to be intent on spinning everything to the most negative conclusion possible - accentuating the negative and ignoring the positive. Why?
Cant figure it out why it didnt drop like a rock it cant be because ot the cash value. The cash can disappear fast and then what would be its appeal . Other then other promising trials that have no guar. with a black eye today. It just straight lined that scary trading ? isnt that strange